Lumefantrine USP: API of Choice for Pharma Firms
Malaria remains a persistent global health challenge, particularly across regions where Plasmodium falciparum has developed resistance to traditional monotherapies. To counter this, international health protocols heavily emphasize Artemisinin-based Combination Therapies (ACTs). Within these co-formulations, Lumefantrine serves as a vital partner molecule, offering a prolonged half-life that clears residual parasites after the fast-acting artemisinin derivative completes its initial phase. For pharmaceutical formulators, selecting a high-grade active pharmaceutical ingredient (API) is not simply a matter of procurement; it directly affects drug stability, bio-absorption, and therapeutic consistency. Lumefantrine USP has established itself as the quality benchmark for manufacturers aiming to produce reliable, compliant malaria treatments . The Role of Lumefantrine USP in Artemisinin-Based Combination Therapies The therapeutic strategy behind Artemisinin-Based Combination Therapie...